A new three-part study showed that a delayed-release, extended-release form of methylphenidate could be given to adults in the evening with or without food and would not exert any clinically meaningful effect for at least 10 hours after administration. These positive findings suggest that HLD200 could provide a novel and more flexible alternative to treating attention deficit hyperactivity disorder (ADHD) in children compared to the currently used immediate-release methylphenidate. The design of each study and the intriguing results are reported in the Journal of Child and Adolescent Psychopharmacology.
The article is entitled “Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults.” Coauthors Bev Incledon, Ph.D., Ironshore Pharmaceuticals & Development, Inc., (Grand Cayman, Cayman Islands) and colleagues from University of Maryland School of Pharmacy (Baltimore, MD) and Highland Therapeutics, Inc. (Toronto, Canada) set up a series of studies to be able to evaluate different doses of HLD200, the potential impact of taking the drug in a fasted state or following a high-fat evening meal, and the effects, if any, of a low-fat versus a medium-fat breakfast. The authors also evaluated different dosing strategies.
Source: Read Full Article